Developer docs
API playgroundTry for free, no card

Search company profiles

SAI MedPartners

Full company profile

uuid000an65

Namestring
SAI MedPartners
Legal namestring
SAI MedPartners LLC
Websiteurl
sai-med.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

SAI MedPartners is a global life sciences strategy consultancy that serves pharmaceutical, biotechnology, and medical device companies. The firm provides integrated services across four pillars: competitive intelligence and benchmarking, market research and forecasting, market access and pricing, and path-to-market positioning. With 250+ employees across eight offices in Reading (HQ), Waltham, London, Zurich, Beijing, Shanghai, and Bangalore, SAI supports hundreds of enterprise healthcare clients across the product lifecycle — from preclinical development through loss of exclusivity. According to company claims, SAI provided strategic support to 31% of new molecular entities launched since 2021. The firm operates through direct, senior-level enterprise consulting engagements with multi-year contracts and quote-based pricing.

The company's offerings span human-delivered consulting, syndicated subscription products, and proprietary technology. Core acquired brands include Fulcrum Research Group (custom quantitative and qualitative market research), PharmaForce International (syndicated benchmarking reports updated annually across oncology, immunology, cardiovascular, CNS, and ophthalmology, with a 20+ year track record), IDEA Pharma (path-to-market strategy using the FIVE-X framework), and The Dunn Group (competitive intelligence). Technology-enabled products include IntelliTraQ (knowledge management), Deployment Analyzer (global sales force deployment data, updated semi-annually), and Synthetic Users — an AI platform generating synthetic healthcare stakeholders (physicians, patients, caregivers) that participate in dynamic interview-based research, with the company claiming up to 93% parity to human respondents. The Synthetic Users platform operates within a SOC 2 Type 2-compliant closed environment.

SAI MedPartners is privately held, backed by Northlane Capital Partners since June 2022. The PE investment funded a roll-up strategy with acquisitions of Fulcrum Research Group (January 2023), PharmaForce International (March 2023), IDEA Pharma (November 2024), and The Dunn Group (December 2025), expanding capabilities and brand portfolio. Founder Erik Nordhoy remains CEO; the leadership team includes BU Presidents for CI/Benchmarking, Strategic Consulting/Analytics (two BU presidents covering Fulcrum and IDEA), Asia (Celia Deng), a CFO (Anders Eriksson), a Chief Medical & Innovation Officer (Alexander Gray), and an EVP of Corporate Development (John Barry). Revenue is not publicly disclosed.

Short descriptiontext

SAI MedPartners is a global life sciences strategy consultancy serving pharmaceutical, biotechnology, and medical device companies with competitive intelligence, market research, forecasting, market access, and path-to-market positioning services across eight offices in the U.S., Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersReading, United States
HQ citystring
Reading
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences consulting, competitive intelligence pharma, pharmaceutical market research, healthcare forecasting services, market access strategy
Industry2 codes
PRIMARYHLAGAOAG
Medical Affairs, Scientific Communications & HEOR FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYBPAFADAJ
Healthcare & Life Sciences PR
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Health Services8000
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Strategy Consulting
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Consulting Services
TypeProfessional Services
Description

Consulting engagements providing competitive intelligence, market research, forecasting, market access strategy, and path-to-market positioning services to pharmaceutical, biotechnology, and medical device companies.

sai-med.com
2Syndicated Reports and Subscriptions
TypeSubscription Recurring
Description

PharmaForce International provides syndicated benchmarking reports covering commercial strategies across therapeutic areas including oncology, immunology, cardiovascular, CNS, and ophthalmology, updated annually.

sai-med.com
3Deployment Analyzer Subscriptions
TypeSubscription Recurring
Description

Online tool subscription providing sales force deployment data, updated twice annually per region, with at least five years of historical data. Subscriptions can be tailored by country or therapeutic category.

sai-med.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise consulting services - custom engagements
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; services offered as custom consulting engagements for enterprise healthcare companies.

sai-med.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Fulcrum Research Group
Description

SAI MedPartners' dedicated healthcare market research division providing custom quantitative and qualitative market research insights

sai-med.com
+3 more records
Core offering1 text field

SAI MedPartners is a global life sciences strategy consultancy that delivers competitive intelligence, market research, forecasting, and market access services to pharmaceutical, biotechnology, and medical device companies. The firm combines deep therapeutic-area expertise with proprietary technology platforms, including an AI-powered synthetic user simulation tool, to support strategic decision-making across the product lifecycle.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 31% of new molecular entities launched since 2021 received strategic support from SAI
+3 more records
Product overview1 text field

SAI MedPartners is a global life sciences strategy consultancy offering integrated insights across four core pillars: Competitive Intelligence & Benchmarking, Market Research & Forecasting, Market Access & Pricing, and Path-to-Market & Positioning. The company operates as a unified platform combining consulting services with technology-enabled products. Key offerings include Competitive Intelligence consulting, Fulcrum Research Group (custom market research), IDEA Pharma (path-to-market strategy), and PharmaForce International (syndicated benchmarking). Technology products include Synthetic Users (AI-generated stakeholder simulations), Deployment Analyzer (sales force analytics tool), Syndicated Reports (therapy area benchmarking), and IntelliTraQ (competitive intelligence monitoring). Recent acquisitions of The Dunn Group, PharmaForce International, and Fulcrum Research Group have expanded the portfolio.

Product and service12 records
1Competitive Intelligence
CategoryCompetitive Intelligence
2Market Research
CategoryMarket Research
3Life Cycle Management
CategoryLife Sciences Strategy Consulting
4Forecasting
CategoryForecasting & Analytics
5Market Access + Pricing
CategoryMarket Access Consulting
6Path-to-Market + Positioning
CategoryLaunch Strategy Consulting
7Synthetic Users
CategoryAI Research Platform
8IntelliTraQ
CategoryCompetitive Intelligence Platform
9Deployment Analyzer
CategoryPharmaceutical Analytics Platform
10PharmaForce Syndicated Reports
CategorySyndicated Research
11TheraTraQ
CategoryTherapeutic Intelligence
12IDEA Pharma Services
CategoryPharmaceutical Strategy Consulting
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

SAI MedPartners acquired The Dunn Group, a competitive intelligence firm based in Totowa, NJ, to enhance its competitive intelligence services. The acquisition strengthens SAI's market position and deepens client relationships in the pharmaceutical, biotechnology, and medical device industries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

SAI MedPartners acquired PharmaForce International, a market research and syndicated benchmarking company providing comprehensive commercial competitive benchmarking solutions for pharmaceutical and biotech companies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Northlane Capital added Fulcrum Research Group to SAI MedPartners. Fulcrum is a healthcare-focused consulting firm providing custom quantitative and qualitative market research services to pharmaceutical and biotech clients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership with China Policy Center for policy interpretation and industry execution assessment, addressing industry players' hot topics and leading to panel discussions exploring executional optimization solutions.

5China CDC and China Association of Vaccine
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for BeSD (Best Immunization Practice) localization to support China's National Immunization Program. Includes design and execution support, optimization of national vaccine strategy with evidence support, and whitepaper publications.

sai-med.com
Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global consulting firm with a Life Sciences practice providing economic, strategic, and litigation consulting to pharma. Overlaps with SAI in forecasting, market access, HEOR, and pricing strategy but from a broader economic/strategy angle rather than dedicated CI focus.

TypeBroad incumbent
Description

Global leader in life sciences technology, analytics, and consulting with deep strategy, CI, market access, real-world evidence, and primary market research offerings. Overlaps with SAI across most of its four pillars but operates at vastly greater scale and a much broader portfolio.

3ZS Associates
TypeDirect peer
Description

Large global management consulting firm dedicated to healthcare and life sciences, providing strategy, market access, sales/marketing analytics, and CI services to pharma and biotech clients. Closely comparable to SAI in target customer (pharma/biotech leadership), consulting-led GTM, and therapeutic-area depth.

TypeBroad incumbent
Description

End-to-end commercial services provider to life sciences companies, including CI, market research, market access, and HEOR (following its integration of parts of the former Intellisphere/Primary Intelligence practice). Comparable in many SAI service lines though broader in execution/commercialization services.

TypeDirect peer
Description

Boutique life sciences strategy consultancy specializing in market access, pricing, and HEOR for pharma and biotech clients. Direct competitor to SAI's Market Access + Pricing pillar with analogous senior-led, custom-engagement model.

TypeRegional player
Description

Smaller healthcare-focused competitive intelligence and market research consultancy serving US-based pharma/biotech. Comparable niche, though lacks SAI's Asia footprint and PE-backed scale.

7Trinity Partners
TypeDirect peer
Description

Healthcare-focused strategy consulting firm serving biopharmaceutical, medical device, and diagnostics clients with CI, market access, and commercial strategy engagements. Highly analogous to SAI in service mix, therapeutic depth, and senior-consultant-led delivery model.

TypeDirect peer
Description

Healthcare market research and consulting firm serving pharma with custom qualitative and quantitative research, patient research, and CI. Comparable to Fulcrum Research Group sub-brand within SAI in market research methodology and client base.

TypeDirect peer
Description

Specialized life sciences competitive intelligence and strategy consultancy offering CI, market research, and brand strategy to pharma and biotech. Direct competitor in the SAI core CI business with comparable senior-led engagement model and KOL network depth.

10M3 (MDOutlook / Practice Fusion research adjacencies)
TypeEmerging player
Description

Global healthcare data and market research platform with syndicated panels and physician insights. Adjacent rather than direct: comparable in KOL/physician panel data and syndicated benchmarking categories to SAI's Deployment Analyzer and PharmaForce offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SAI MedPartners

Life Sciences Strategy Consultingsai-med.com

SAI MedPartners is a global life sciences strategy consultancy serving pharmaceutical, biotechnology, and medical device companies with competitive intelligence, market research, forecasting, market access, and path-to-market positioning services across eight offices in the U.S., Europe, and Asia.

What SAI MedPartners does

SAI MedPartners is a global life sciences strategy consultancy that serves pharmaceutical, biotechnology, and medical device companies. The firm provides integrated services across four pillars: competitive intelligence and benchmarking, market research and forecasting, market access and pricing, and path-to-market positioning. With 250+ employees across eight offices in Reading (HQ), Waltham, London, Zurich, Beijing, Shanghai, and Bangalore, SAI supports hundreds of enterprise healthcare clients across the product lifecycle — from preclinical development through loss of exclusivity. According to company claims, SAI provided strategic support to 31% of new molecular entities launched since 2021. The firm operates through direct, senior-level enterprise consulting engagements with multi-year contracts and quote-based pricing.

The company's offerings span human-delivered consulting, syndicated subscription products, and proprietary technology. Core acquired brands include Fulcrum Research Group (custom quantitative and qualitative market research), PharmaForce International (syndicated benchmarking reports updated annually across oncology, immunology, cardiovascular, CNS, and ophthalmology, with a 20+ year track record), IDEA Pharma (path-to-market strategy using the FIVE-X framework), and The Dunn Group (competitive intelligence). Technology-enabled products include IntelliTraQ (knowledge management), Deployment Analyzer (global sales force deployment data, updated semi-annually), and Synthetic Users — an AI platform generating synthetic healthcare stakeholders (physicians, patients, caregivers) that participate in dynamic interview-based research, with the company claiming up to 93% parity to human respondents. The Synthetic Users platform operates within a SOC 2 Type 2-compliant closed environment.

SAI MedPartners is privately held, backed by Northlane Capital Partners since June 2022. The PE investment funded a roll-up strategy with acquisitions of Fulcrum Research Group (January 2023), PharmaForce International (March 2023), IDEA Pharma (November 2024), and The Dunn Group (December 2025), expanding capabilities and brand portfolio. Founder Erik Nordhoy remains CEO; the leadership team includes BU Presidents for CI/Benchmarking, Strategic Consulting/Analytics (two BU presidents covering Fulcrum and IDEA), Asia (Celia Deng), a CFO (Anders Eriksson), a Chief Medical & Innovation Officer (Alexander Gray), and an EVP of Corporate Development (John Barry). Revenue is not publicly disclosed.

SAI MedPartners firmographics

Firmographics
Name
SAI MedPartners
Legal name
SAI MedPartners LLC
Website
https://sai-med.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
251–500 employees
Short description
SAI MedPartners is a global life sciences strategy consultancy serving pharmaceutical, biotechnology, and medical device companies with competitive intelligence, market research, forecasting, market access, and path-to-market positioning services across eight offices in the U.S., Europe, and Asia.
Ownership category
akta.pro rank

SAI MedPartners industry classification

Industry
Product category
Life Sciences Strategy Consulting
NAICS
Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAOAG
Medical Affairs, Scientific Communications & HEOR FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYBPAFADAJ
Healthcare & Life Sciences PR

Keywords

  • Life sciences consulting
  • Competitive intelligence pharma
  • Pharmaceutical market research
  • Healthcare forecasting services
  • Market access strategy

Where SAI MedPartners is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United States
HQ region
North America

Offices7 records

Markets served

SAI MedPartners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Consulting Services: Consulting engagements providing competitive intelligence, market research, forecasting, market access strategy, and path-to-market positioning services to pharmaceutical, biotechnology, and medical device companies.
  2. Syndicated Reports and Subscriptions: PharmaForce International provides syndicated benchmarking reports covering commercial strategies across therapeutic areas including oncology, immunology, cardiovascular, CNS, and ophthalmology, updated annually.
  3. Deployment Analyzer Subscriptions: Online tool subscription providing sales force deployment data, updated twice annually per region, with at least five years of historical data. Subscriptions can be tailored by country or therapeutic category.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise consulting services - custom engagements

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

SAI MedPartners product offering

Product offering

Core offering

SAI MedPartners is a global life sciences strategy consultancy that delivers competitive intelligence, market research, forecasting, and market access services to pharmaceutical, biotechnology, and medical device companies. The firm combines deep therapeutic-area expertise with proprietary technology platforms, including an AI-powered synthetic user simulation tool, to support strategic decision-making across the product lifecycle.

Product overview

SAI MedPartners is a global life sciences strategy consultancy offering integrated insights across four core pillars: Competitive Intelligence & Benchmarking, Market Research & Forecasting, Market Access & Pricing, and Path-to-Market & Positioning. The company operates as a unified platform combining consulting services with technology-enabled products. Key offerings include Competitive Intelligence consulting, Fulcrum Research Group (custom market research), IDEA Pharma (path-to-market strategy), and PharmaForce International (syndicated benchmarking). Technology products include Synthetic Users (AI-generated stakeholder simulations), Deployment Analyzer (sales force analytics tool), Syndicated Reports (therapy area benchmarking), and IntelliTraQ (competitive intelligence monitoring). Recent acquisitions of The Dunn Group, PharmaForce International, and Fulcrum Research Group have expanded the portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • Fulcrum Research Group: SAI MedPartners' dedicated healthcare market research division providing custom quantitative and qualitative market research insights
  • PharmaForce International
  • IDEA Pharma
  • Synthetic Users

Products and services

  • Competitive Intelligence
  • Market Research
  • Life Cycle Management
  • Forecasting
  • Market Access + Pricing
  • Path-to-Market + Positioning
  • Synthetic Users
  • IntelliTraQ
  • Deployment Analyzer
  • PharmaForce Syndicated Reports
  • TheraTraQ
  • IDEA Pharma Services

Quantifiable outcome

  • 31% of new molecular entities launched since 2021 received strategic support from SAI
  • +3 more outcomes

Companies that use SAI MedPartners

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

SAI MedPartners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

SAI MedPartners partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • The Dunn GroupcoreStrategic or Co-development Partner · 1 December 2025SAI MedPartners acquired The Dunn Group, a competitive intelligence firm based in Totowa, NJ, to enhance its competitive intelligence services. The acquisition strengthens SAI's market position and deepens client relationships in the pharmaceutical, biotechnology, and medical device industries.
  • PharmaForce InternationalcoreStrategic or Co-development Partner · 1 March 2023SAI MedPartners acquired PharmaForce International, a market research and syndicated benchmarking company providing comprehensive commercial competitive benchmarking solutions for pharmaceutical and biotech companies.
  • Fulcrum Research GroupcoreStrategic or Co-development Partner · 1 January 2023Northlane Capital added Fulcrum Research Group to SAI MedPartners. Fulcrum is a healthcare-focused consulting firm providing custom quantitative and qualitative market research services to pharmaceutical and biotech clients.
  • China Policy CenterminorStrategic or Co-development PartnerStrategic partnership with China Policy Center for policy interpretation and industry execution assessment, addressing industry players' hot topics and leading to panel discussions exploring executional optimization solutions.
  • China CDC and China Association of VaccineminorStrategic or Co-development PartnerPartnership for BeSD (Best Immunization Practice) localization to support China's National Immunization Program. Includes design and execution support, optimization of national vaccine strategy with evidence support, and whitepaper publications.

Scale indicators6 records

Expansion highlights6 records

SAI MedPartners competitors and assessment

Company assessment

Broad incumbents

  • Charles River Associates (Life Sciences practice): Global consulting firm with a Life Sciences practice providing economic, strategic, and litigation consulting to pharma. Overlaps with SAI in forecasting, market access, HEOR, and pricing strategy but from a broader economic/strategy angle rather than dedicated CI focus.
  • IQVIA: Global leader in life sciences technology, analytics, and consulting with deep strategy, CI, market access, real-world evidence, and primary market research offerings. Overlaps with SAI across most of its four pillars but operates at vastly greater scale and a much broader portfolio.
  • EVERSANA: End-to-end commercial services provider to life sciences companies, including CI, market research, market access, and HEOR (following its integration of parts of the former Intellisphere/Primary Intelligence practice). Comparable in many SAI service lines though broader in execution/commercialization services.

Direct peers

  • ZS Associates: Large global management consulting firm dedicated to healthcare and life sciences, providing strategy, market access, sales/marketing analytics, and CI services to pharma and biotech clients. Closely comparable to SAI in target customer (pharma/biotech leadership), consulting-led GTM, and therapeutic-area depth.
  • CBPartners: Boutique life sciences strategy consultancy specializing in market access, pricing, and HEOR for pharma and biotech clients. Direct competitor to SAI's Market Access + Pricing pillar with analogous senior-led, custom-engagement model.
  • Trinity Partners: Healthcare-focused strategy consulting firm serving biopharmaceutical, medical device, and diagnostics clients with CI, market access, and commercial strategy engagements. Highly analogous to SAI in service mix, therapeutic depth, and senior-consultant-led delivery model.
  • Adelphi Group (Adelphi Research by Design): Healthcare market research and consulting firm serving pharma with custom qualitative and quantitative research, patient research, and CI. Comparable to Fulcrum Research Group sub-brand within SAI in market research methodology and client base.
  • Prescient Healthcare Group: Specialized life sciences competitive intelligence and strategy consultancy offering CI, market research, and brand strategy to pharma and biotech. Direct competitor in the SAI core CI business with comparable senior-led engagement model and KOL network depth.

Regional players

Emerging players

  • M3 (MDOutlook / Practice Fusion research adjacencies): Global healthcare data and market research platform with syndicated panels and physician insights. Adjacent rather than direct: comparable in KOL/physician panel data and syndicated benchmarking categories to SAI's Deployment Analyzer and PharmaForce offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

SAI MedPartners social profiles

Digital presence

SAI MedPartners compliance and trust

Trust signal

Compliance1 record

SAI MedPartners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SAI MedPartners leadership team

Management profile

Number of profiles

Profiles11 records

SAI MedPartners subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

SAI MedPartners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SAI MedPartners M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAI MedPartners

What does SAI MedPartners do?

SAI MedPartners is a global life sciences strategy consultancy that delivers competitive intelligence, market research, forecasting, and market access services to pharmaceutical, biotechnology, and medical device companies. The firm combines deep therapeutic-area expertise with proprietary technology platforms, including an AI-powered synthetic user simulation tool, to support strategic decision-making across the product lifecycle.

Is SAI MedPartners a public or private company?

SAI MedPartners is a private company. It is classified as private equity controlled and is currently operating.

When was SAI MedPartners founded?

SAI MedPartners was founded in 2011. It employs 251 to 500 people.

Where is SAI MedPartners based?

SAI MedPartners is headquartered in Reading, United States, in the North America region.

How does SAI MedPartners make money?

Three revenue lines are on record. Strategic Consulting Services are the primary driver. The others are syndicated Reports and Subscriptions and deployment Analyzer Subscriptions.

Who are SAI MedPartners's main competitors?

Broad incumbents on record are Charles River Associates (Life Sciences practice), IQVIA and EVERSANA. Direct peers are ZS Associates, CBPartners, Trinity Partners, Adelphi Group (Adelphi Research by Design) and Prescient Healthcare Group. Alligent (now NFP/Life Sciences consulting affiliates) is listed as a regional player. M3 (MDOutlook / Practice Fusion research adjacencies) is listed as an emerging player.

Does SAI MedPartners have an API?

No public API is recorded for SAI MedPartners.

What industry is SAI MedPartners in?

SAI MedPartners's product category is Life Sciences Strategy Consulting. Its primary akta.pro industry code is HLAGAOAG, Medical Affairs, Scientific Communications & HEOR FSP, with a secondary code of BPAFADAJ, Healthcare & Life Sciences PR. Its NAICS code is 54169 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AxiosScoop: Northlane-backed SAI MedPartners for saleNorthlane Capital Partners is selling pharma consultancy SAI MedPartners, according to Axios Pro sources familiar with the matter. The sale comes as SAI MedPartners enters a crowded market for sponsor-backed pharma consulting companies. The deal signals continued consolidation and dealmaking activity in the pharma consulting sector.openPR.comHealthcare Business Intelligence Market Set for Steady Growth to US$ 16.53 Billion by 2033, Dominated by North America's 46% ShareThe global Healthcare Business Intelligence Market reached US$8.51 billion in 2024 and is projected to grow to US$16.53 billion by 2033, reflecting a compound annual growth rate of 7.5% during the forecast period 2025-2033. Key industry developments include strategic acquisitions such as SAI MedPartners acquiring The Dunn Group, Smarter Technologies acquiring Pieces Technologies, and CitiusTech acquiring Health Data Movers in 2025, alongside product launches by major vendors including IBM, Oracle, and SAS Institute. Regional analysis shows North America holding the largest market share at 46%, driven by advanced healthcare IT infrastructure and high EHR adoption, while Asia Pacific represents the fastest-growing region at 29%.PharmiWeb.comSAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn GroupSAI MedPartners has acquired The Dunn Group, a competitive intelligence firm focused on the pharmaceutical and biotechnology industries, headquartered in Totowa, NJ. The acquisition is intended to enhance SAI MedPartners' core competitive intelligence offerings and deepen its service capabilities for clients across the product development lifecycle. Northlane Capital Partners, which partnered with SAI management to acquire the firm in June 2022, facilitated this transaction.Business Wire BlogSAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn GroupSAI MedPartners has acquired The Dunn Group, a competitive intelligence firm serving the pharmaceutical and biotechnology industries. The acquisition will enhance SAI's core competitive intelligence offering by adding TDG's capabilities in pipeline analysis, therapy area tracking, and analogue assessments. Northlane Capital Partners, which partnered with management to acquire SAI in June 2022, facilitated the transaction.Business Wire BlogSAI MedPartners Expands Strategic Service Offering Through Acquisition of IDEA PharmaSAI MedPartners acquired IDEA Pharma, a London-based firm specializing in pharmaceutical path-to-market strategy. The acquisition strengthens SAI's strategic services for biopharma clients, covering drug discovery to market launch. It is SAI's third strategic acquisition, following Fulcrum Research Group and PharmaForce International.ThemiddlemarketSAI MedPartners Acquires Fulcrum ResearchSAI MedPartners has acquired Fulcrum Research Group, a market research consulting firm specializing in healthcare and biopharmaceuticals. This acquisition is intended to complement SAI’s competitive intelligence expertise and enhance its value proposition as a decision support partner for pharmaceutical and biotech sectors.Sai-MedSAI MedPartners Expands Its Strategic Insights Capabilities Through Acquisition of Fulcrum Research GroupSAI MedPartners has acquired Fulcrum Research Group to enhance its strategic insights capabilities in the pharmaceutical and medical device industries. This acquisition aligns with SAI's goal of becoming a leading global consultancy by further investing in resources and expanding service capabilities. Fulcrum, founded in 2010, specializes in primary market research specifically for healthcare and biopharmaceuticals.